The main goal is to carry out research into rare skeletal diseases
An agreement has been signed between IBM’s ‘Clinical Genomics’ group, based in Haifa, Israel, and the Rizzoli Orthopaedic Institute, to carry out research into rare skeletal diseases. The Rizzoli Medical Genetics centre is the second partner, after the Harvard Medical School in Boston, to be chosen by IBM for this research project. At their outpatient clinic, the Rizzoli Institute has developed a software program to process and analyse the clinical data of patients suffering from rare skeletal diseases, to find new answers.
The project, being developed by researchers from the Rizzoli Medical Genetics Division and the IBM Research Lab, as part of an agreement between the Emilia-Romagna Region and the Israeli Ministry for Innovation and Development, concerns BioMIMs: the patient is at the centre of a system that “maps out” all his clinical data, genetic test results, x-ray images, personal data and family medical history. Thanks to this substantial amount of information, and comparison with other patients’ data that BioMIMs technology allows, it will be possible to improve clinical knowledge regarding rare skeletal diseases and to define an individual patient’s diagnosis and treatment more precisely.
Email a friend